ஐ.எஸ்.எஸ்.என்: 2576-1471
Gallagher PiO
Accumulation of effective immunity against SARS-CoV2 contagion and non-SARS human coronaviruses (hCoVs) is likely possible in patients with hematologic malignancies who have experienced a hematopoietic stem cell transplantation (HSCT). These findings from a study of patients with hematologic malignancies versus healthy volunteers were presented at the 2021 transplantation and cellular therapy meetings of CIBMTR and ASTCT.